Article | Published:

Increased Use of Medications for Erectile Dysfunction in Men With Ulcerative Colitis and Crohn’s Disease Compared to Men Without Inflammatory Bowel Disease: A Nationwide Cohort Study

The American Journal of Gastroenterologyvolume 113pages13551362 (2018) | Download Citation




Men with inflammatory bowel disease (IBD) may have decreased sexual function due to factors related to the underlying disease, medication, and/or surgery. We aimed to examine the use of erectile dysfunction (ED) medications in men with IBD.


This is a nationwide cohort study based on the Danish registries, comprising all men >18 years old with IBD during 1 January 1995 through December 2016. The cohorts included 31,498 men with IBD and 314,980 age-matched men without IBD. Our main outcome was a first prescription of an ED medication. Cox regression analyses were used to estimate the hazard rate (HR) for use of ED medications, controlled for multiple time-varying covariates.


Overall, 21,966 (69.7%) men had ulcerative colitis (UC) while 9532 (30.3%) had Crohn’s disease (CD). Men with a first ED prescription numbered 3749 (11.9%) (men with IBD) and 30,635 (9.7%) (men without IBD). Adjusting for central nervous system and intestinal anti-inflammatory medications, systemic corticosteroids and co-morbidities, the HR was 1.19 (95% CI: 1.13–1.26) (IBD and no prior IBD operation), and 1.31 (95% CI: 1.20–1.43) (IBD and prior IBD operation). The adjusted HR for UC was 1.17 (95% CI: 1.10–1.24) (no operation) and 1.43 (95% CI: 1.27–1.61) (prior operation), and for CD 1.26 (95% CI: 1.15–1.38) (no operation) and 1.20 (95% CI: 1.06–1.35) (prior operation).


Men with IBD are more likely to fill an ED prescription than men without IBD. This result is significant regardless of a history of IBD surgery.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Nørgård BM, Nielsen J, Fonager K, et al. The incidence of ulcerative colitis (1995-2011) and Crohn’s disease (1995-2012)—based on nationwide Danish registry data. J Crohns Colitis. 2014;8:1274–80.

  2. 2.

    O’Toole A, Winter D, Friedman S. Review article: the psychosexual impact of inflammatory bowel disease in male patients. Aliment Pharmacol Ther. 2014;39:1085–94.

  3. 3.

    Mantzouranis G, Fafliora E, Glanztounis G et al. Inflammatory bowel disease and sexual function in male and female patients: an update on evidence in the past ten years. J Crohn Colitis 2015;9:1160–8.

  4. 4.

    Ghazi LJ, Patil SA, Cross RK. Sexual dysfunction in inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:939–47.

  5. 5.

    Doumas M, Lazaridis A, Katsiki N, et al. PDE-5 inhibitors: clinical points. Curr Drug Targets. 2015;16:420–6.

  6. 6.

    Porst H, Hell-Momeni K, Büttner H. Chronic PDE-5 inhibition in patients with erectile dysfunction—a treatment approach using tadalafil once-daily. Expert Opin Pharmacother. 2012;13:1481–94.

  7. 7.

    Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009;151:650.

  8. 8.

    Burke RM, Evans JD. Avanafil for treatment of erectile dysfunction: review of its potential. Vasc Health Risk Manag. 2012;8:517–23.

  9. 9.

    Timmer A, Bauer A, Dignass A, et al. Sexual function in persons with inflammatory bowel disease: a survey with matched controls. Clin Gastroenterol Hepatol. 2007;5:87–94.

  10. 10.

    Timmer A, Bauer A, Kemptner D, et al. Determinants of male sexual function in inflammatory bowel disease: a survey-based cross sectional analysis in 280 men. Inflamm Bowel Dis. 2007;13:1236–43.

  11. 11.

    Marin L, Manosa M, Garcia-Planella E, et al. Sexual function and patients’ perceptions in inflammatory bowel disease: a case-control survey. J Gastroenterol. 2013;48:713–20.

  12. 12.

    Rivière P, Zallot C, Desobry P, et al. Frequency of and factors associated with sexual dysfunction in patients with inflammatory bowel disease. J Crohns Colitis. 2017;11:1347–52.

  13. 13.

    Knowles SR, Gass C, Macrae F. Illness perceptions in IBD influence psychological status, sexual health and satisfaction, body image and relational functioning: a preliminary exploration using Structural Equation Modeling. J Crohns Colitis. 2013;7:e344–50.

  14. 14.

    Mountifield R, Bampton P, Prosser R, et al. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis. 2009;15:720–5.

  15. 15.

    Wang JY, Hart SL, Wilkowski KS, et al. Gender-specific differences in pelvic organ function after proctectomy for inflammatory bowel disease. Dis Colon Rectum. 2011;54:66–76.

  16. 16.

    Farouk R, Pemberton JH, Wolff BG, et al. Functional outcomes after ileal pouch-anal anastomosis for chronic ulcerative colitis. Ann Surg. 2000;231:919–26.

  17. 17.

    Lindsey I, George BD, Kettlewell MG, et al. Impotence after mesorectal and close rectal dissection for inflammatory bowel disease. Dis Colon Rectum. 2001;44:831–5.

  18. 18.

    van Balkom KA, Beld MP, Visschers, et al. Long-term results after restorative proctocolectomy with ileal pouch-anal anastomosis at a young age. Dis Colon Rectum. 2012;55:939–47.

  19. 19.

    Rosen RC, Cappelleri JC, Gendrano N 3rd. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14:226–44.

  20. 20.

    Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–9.

  21. 21.

    Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–90.

  22. 22.

    Pottegård A, Schmidt SA, Wallach-Kildemoes H, et al. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46:798.

  23. 23.

    Rothman KJ . Case-control studies. Modern epidemiology. 3rd edition Philadelphia, PA: LWW; 2008. p. 124–125.

  24. 24.

    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373–83.

  25. 25.

    O’Toole A, de Silva PS, Marc LG, et al. Sexual dysfunction in men with inflammatory bowel disease: a new IBD-specific scale. Inflamm Bowel Dis. 2018;24:310–6.

  26. 26.

    Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: A nationwide cohort study 1979-2011. Gut. 2014;63:1607–16.

  27. 27.

    Fonager K, Sorensen HT, Rasmussen SN, et al. Assessment of the diagnoses of Crohn’s disease and ulcerative colitis in a Danish hospital information system. Scand J Gastroenterol. 1996;31:154–9.

  28. 28.

    Szathmari M, Vasarhelyi B, Treszl A, et al. Association of dehydroepiandrosterone sulfate and testosterone deficiency with bone turnover in men with inflammatory bowel disease. Int J Colorectal Dis. 2002;17:1763–6.

  29. 29.

    Schulte CM. Review article: Bone disease in inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20(suppl. 4):43–9.

  30. 30.

    Bokemeyer B, Hardt J, Huppe D, et al. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohn’s Colitis. 2013;7:355–68.

  31. 31.

    Cao S, Gan Y, Dong X, et al. Association of quantity and duration of smoking with erectile dysfunction: a dose-response meta-analysis. J Sex Med. 2014;11:2376–84.

  32. 32.

    Verze P, Margreiter M, Esposito K, et al. The link between cigarette smoking and erectile dysfunction: a systematic review. Eur Urol Focus. 2015;1:39–46.

  33. 33.

    Bernstein CN. Review article: changes in the epidemiology of inflammatory bowel disease-clues for aetiology. Aliment Pharmacol Ther. 2017;46:911–9.

Download references

Author information


  1. Center for Crohn’s and Colitis, Brigham and Women’s Hospital, Chestnut Hill, MA, USA

    • S Friedman MD
    •  & BM Nørgård MD, PhD, DMSc
  2. Harvard Medical School, Boston, MA, USA

    • S Friedman MD
    •  & BM Nørgård MD, PhD, DMSc
  3. Center for Clinical Epidemiology, Odense University Hospital, and Research Unit of Clinical Epidemiology, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark

    • S Friedman MD
    • , B Magnussen MSc
    • , MD Larsen MSc, PhD
    •  & BM Nørgård MD, PhD, DMSc
  4. Department of Gastroenterology, Beaumont Hospital and Royal College of Surgeons of Ireland, Dublin, Ireland

    • A O’Toole MD
  5. Centre of Andrology and Fertility Clinic, Department D, Odense University Hospital, and Research Unit of Human Reproduction, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark

    • J Fedder MD, MSc, PhD


  1. Search for S Friedman MD in:

  2. Search for B Magnussen MSc in:

  3. Search for A O’Toole MD in:

  4. Search for J Fedder MD, MSc, PhD in:

  5. Search for MD Larsen MSc, PhD in:

  6. Search for BM Nørgård MD, PhD, DMSc in:

Guarantor of the article

S Friedman.

Specific author contributions

SF, BMN: funding, conception, design, data collection, assistance with data analysis, interpretation of results, manuscript writing and editing, approved the final version. BM: design, data collection, data analysis, interpretation of results, manuscript editing, approved the final version. AOT: conception, interpretation of results, manuscript writing and editing, approved the final version. MDL: design, assistance with data analysis, interpretation of results, manuscript editing, approved the final version. JF: interpretation of results, manuscript editing, approved the final version.

Financial support

The study was supported by a Crohn’s & Colitis Foundation of America (CCFA), Senior Research Award.

Potential competing interests


Corresponding author

Correspondence to S Friedman MD.


Medication Codes: alprostadil (ATC code: G04BE01); sildenafil (ATC code: G04BE03); tadalafil (ATC code: G04BE08); vardenafil (ATC code: G04BE09); avanafil (ATC code: G04BE10); aviptadil (ATC code: G04BE30); intestinal anti-inflammatory agents for IBD (ATC code A07E including all underlying subgroups); corticosteroids for systemic use (ATC code H02A including all subgroups); psychoanaleptics (ATC code N06 with all subgroups); antipsychotics (ATC code N05A); anxiolytics (ATC code N05B with all subgroups); sedative/hypnotics (ATC code N05C with all subgroups); antiepileptics (ATC code N03 with all subgroups); opioids (ATC code N02A with all subgroups; azathioprine (ATC L04AX01); 6-mercaptourine (ATC L01BB02); methotrexate (ATC L01BA01/L04AX03).

Surgical Codes: UC—KJFH; i.e., all types of colectomies; and colectomy codes of 45020, 45060, 45080, 45840, or 45880. CD—KJFB00, KJFB01, KJFB20/21/30/31, KJFB33, KJFB34, KJFB40/41/43/44/46/47/50/51/60/61/63/64, KJFB96, KJFB97, KJFH00/01/10/11/20/96, KJGB00/01/10/11/30/31, KJFA60, 43440, 43460, 43520, 43540, 43680, 43700, 43740, 43760, 43780, 43800, 43820, 43840, 43860, 43880, 44060, 44120, 44150, 44160, 44790, 44900, 44920, 44940, 44960, 44980, 45020, 45060, 45080, 45100, 45120, 45200, 45240, 45320, 45480, 45690, 45840, 45860, 45880, 46290.

About this article

Publication history